Shape Therapeutics and Rett Syndrome Research Trust Announce Partnership to Advance a One-Time AI-Designed RNA Editing Therapy for Rett Syndrome

Seattle-based Shape Therapeutics, a leader in RNA editing-based gene therapy, is partnering with the Rett Syndrome Research Trust (RSRT) to advance SHP-401, an investigational one-time gene therapy for Rett syndrome. The collaboration will evaluate Shape’s intravenously delivered RNAfix® gene therapy in non-human primates (NHP).